FMP
ESSA Pharma Inc.
EPIX
NASDAQ
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
6.08 USD
-0.04 (-0.658%)
About
ceo
Dr. David Ross Parkinson M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.essapharma.com
exchange
NASDAQ
Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
CIK
0001633932
ISIN
CA29668H7085
CUSIP
29668H708
Address
999 West Broadway
Phone
17783310962
Country
CA
Employee
50
IPO Date
Mar 13, 2015
Key Executives
